John E. Janik

10.5k total citations · 1 hit paper
142 papers, 7.5k citations indexed

About

John E. Janik is a scholar working on Immunology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, John E. Janik has authored 142 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Immunology, 57 papers in Oncology and 49 papers in Pathology and Forensic Medicine. Recurrent topics in John E. Janik's work include Lymphoma Diagnosis and Treatment (48 papers), T-cell and Retrovirus Studies (40 papers) and Immune Cell Function and Interaction (24 papers). John E. Janik is often cited by papers focused on Lymphoma Diagnosis and Treatment (48 papers), T-cell and Retrovirus Studies (40 papers) and Immune Cell Function and Interaction (24 papers). John E. Janik collaborates with scholars based in United States, United Kingdom and Jamaica. John E. Janik's co-authors include Wyndham H. Wilson, Elaine S. Jaffe, Maryalice Stetler‐Stevenson, Mark Raffeld, Nicole Grant, Kieron Dunleavy, Stefania Pittaluga, Jessica Katz, Anas Younes and Thomas A. Waldmann and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

John E. Janik

136 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

2010 1.0k citations Wyndham H. Wilson, John E. Janik et al. Blood profile →

Peers

Countries citing papers authored by John E. Janik

Since Specialization

Citations

This map shows the geographic impact of John E. Janik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Janik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Janik more than expected).

Fields of papers citing papers by John E. Janik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Janik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Janik. The network helps show where John E. Janik may publish in the future.

Co-authorship network of co-authors of John E. Janik

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Janik. A scholar is included among the top collaborators of John E. Janik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Janik. John E. Janik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors 2025 ·Clinical Cancer Research ·Omid Hamid, Dana B. Cardin, F. Stephen Hodi, Patricia LoRusso, Taha Merghoub, Roberta Zappasodi, Rachana Maniyar, John E. Janik, (unknown), (unknown), Zhiwan Dong, (unknown), James J. Harding	0
2	First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors 2025 ·The Oncologist ·John D. Powderly, Martin Gutierrez, Ani Sarkis Balmanoukian, (unknown), Zhiwan Dong, Lulu Cheng, Xuejun Chen, John E. Janik, Nawel Bourayou, Omid Hamid	0
3	730MO First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies 2022 ·Annals of Oncology ·Martin Gutierrez, (unknown), (unknown), Ani Sarkis Balmanoukian, John E. Janik, (unknown), (unknown), (unknown), Omid Hamid	8
4	Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition 2017 ·Cancer Research ·Rasha Abu Eid, Shamim Ahmad, (unknown), Mason Webb, (unknown), Rajeev Shrimali, Takumi Kumai, Sudha Ananth, Paulo C. Rodrı́guez, Esteban Celis, John E. Janik, Mikayel Mkrtichyan, Samir N. Khleif	61
5	Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis 2017 ·Cancer Immunology Research ·Rajeev Shrimali, Shamim Ahmad, Vivek Verma, Peng Zeng, Sudha Ananth, Pankaj Gaur, Rachel M. Gittelman, Erik Yusko, Catherine Sanders, Harlan Robins, Scott A. Hammond, John E. Janik, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif	117
6	Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma 2016 ·Clinical Cancer Research ·Kamal Sharma, John E. Janik, Deirdre O’Mahony, Donn Stewart, Stefania Pittaluga, Maryalice Stetler‐Stevenson, Elaine S. Jaffe, Mark Raffeld, Thomas A. Fleisher, (unknown), Seth M. Steinberg, Thomas A. Waldmann, John C. Morris	36
7	Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin 2011 ·Molecular Cancer ·Ronan J. Kelly, Ariel López-Chávez, Deborah E. Citrin, John E. Janik, John C. Morris	131
8	Disseminated <i>Strongyloides stercoralis</i> Infection in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma 2011 ·Acta Haematologica ·Donn M. Stewart, Roshan Ramanathan, Siddhartha Mahanty, Daniel P. Fedorko, John E. Janik, John C. Morris	27
9	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response 2011 ·Haematologica ·Weidong Wang, (unknown), (unknown), I. Maric, (unknown), Sattva S. Neelapu, Larry W. Kwak, John E. Janik, Barry L. Gause, Elaine S. Jaffe, Katherine R. Calvo	91
10	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma 2009 ·Blood ·Kieron Dunleavy, Stefania Pittaluga, Myron S. Czuczman, Sandeep S. Davé, George W. Wright, Nicole Grant, Margaret Shovlin, Elaine S. Jaffe, John E. Janik, Louis M. Staudt, Wyndham H. Wilson	371
11	EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies 2009 ·Clinical Cancer Research ·Deirdre O’Mahony, John C. Morris, Maryalice Stetler‐Stevenson, Helen Matthews, Margaret R. Brown, Thomas A. Fleisher, Stefania Pittaluga, Mark Raffeld, Paul S. Albert, Dirk J. Reitsma, Karen Kaucic, Luz Hammershaimb, Thomas A. Waldmann, John E. Janik	35
12	Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells 2009 ·Cytometry Part B Clinical Cytometry ·Indu Arun, (unknown), John E. Janik, (unknown), Constance M. Yuan, David Venzon, Maryalice Stetler‐Stevenson	10
13	Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers 2008 ·Journal of Clinical Oncology ·Wyndham H. Wilson, Kieron Dunleavy, Stefania Pittaluga, Upendra P. Hegde, Nicole Grant, Seth M. Steinberg, Mark Raffeld, Martin Gutierrez, Bruce A. Chabner, Louis M. Staudt, Elaine S. Jaffe, John E. Janik	217
14	Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma 2005 ·Nature Medicine ·Sattva S. Neelapu, Larry W. Kwak, Carol B. Kobrin, Craig W. Reynolds, John E. Janik, Kieron Dunleavy, Therese White, Linda Harvey, Robin Pennington, Maryalice Stetler‐Stevenson, Elaine S. Jaffe, Seth M. Steinberg, Ronald E. Gress, Fran Hakim, Wyndham H. Wilson	85
15	Vaccination by Genetically Modified Dendritic Cells Expressing a TruncatedneuOncogene Prevents Development of Breast Cancer in Transgenic Mice 2004 ·Cancer Research ·Yoshio Sakai, Brian J. Morrison, John D. Burke, (unknown), Masaki Terabe, John E. Janik, Guido Forni, Jay A. Berzofsky, John C. Morris	77
16	Treatment with Tumor Necrosis Factor-α and Granulocyte–Macrophage Colony-Stimulating Factor Increases Epidermal Langerhans' Cell Numbers in Cancer Patients 1999 ·Clinical Immunology ·John E. Janik, Langdon L. Miller, William C. Kopp, Dennis D. Taub, Harry Dawson, (unknown), (unknown), Brendan D. Curti, Kevin C. Conlon, Barbara K. Dunn, (unknown), Robert L. Ullrich, W. Gregory Alvord, Barry L. Gause, Dan L. Longo	19
17	Influence of Interleukin-2 Regimens on Circulating Populations of Lymphocytes After Adoptive Transfer of Anti-CD3-Stimulated T Cells 1996 ·Journal of Immunotherapy ·Brendan D. Curti, Augusto C. Ochoa, Walter J. Urba, W. Gregory Alvord, William C. Kopp, (unknown), (unknown), Stephen P. Creekmore, Barry L. Gause, John E. Janik, Jon Holmlund, (unknown), Robert G. Fenton, Langdon L. Miller, Mario Sznol, John W. Smith, William H. Sharfman, Dan L. Longo	17
18	Phase II Trial of Interleukin 1 and Indomethacin in Treatment of Metastatic Melanoma 1996 ·JNCI Journal of the National Cancer Institute ·John E. Janik, L.L. Miller, Daniele Longo, (unknown), Walter J. Urba, William C. Kopp, Barry L. Gause, Brendan D. Curti, R. G. Fenton, Joost J. Oppenheim, Kevin C. Conlon, Jon Holmlund, Mario Sznol, William H. Sharfman, Ronald G. Steis, Stephen P. Creekmore, W. Gregory Alvord, (unknown), John W. Smith	22
19	The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin 1993 ·New England Journal of Medicine ·John W. Smith, (unknown), W. Gregory Alvord, John E. Janik, William H. Sharfman, Barry L. Gause, Brendan D. Curti, (unknown), Jon Holmlund, (unknown), Mario Sznol, Langdon L. Miller, Masanao Shimizu, Joost J. Oppenheim, (unknown), (unknown), (unknown), Walter J. Urba	98
20	Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma 1992 ·JNCI Journal of the National Cancer Institute ·Mario Sznol, J. W. Clark, John W. Smith, Ronald G. Steis, Walter J. Urba, Larry Rubinstein, (unknown), John E. Janik, William H. Sharfman, R. G. Fenton, Stephen P. Creekmore, (unknown), Kelly Conlon, James Hersey, Joy M. Beveridge, DL Longo	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact